BALB/c nude Related Publications

Aoki K, Akyürek LM, San H, Leung K, Parmacek MS, Nabel EG, Nabel GJ. (2000) Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy. Mol Ther. 1(6):555-65.

Ariazi EA, Lewis-Wambi JS, Gill SD, Pyle JR, Ariazi JL, Kim HR, Sharma CGN, Cordera F, Shupp HA, Li T, Jordan VC. (2006) Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant. J Steroid Biochem Mol Biol. 102(1-5):128-38.

Armentano D, Smith MP, Sookdeo CC, Zabner J, Perricone MA, St. George JA, Wadsworth SC, Gregory RJ. (1999) E4ORF3 requirement for achieving long-term transgene expression from the cytomegalovirus promoter in adenovirus vectors. J Virol. 73(8):7031-4.

Hassid Y, Furman-Haran E, Margalit R, Eilam R, Degani H. (2006) Noninvasive magnetic resonance imaging of transport and interstitial fluid pressure in ectopic human lung tumors. Cancer Res. 66(8):4159-66.

Herbert L, Grosso J, Dorsey M, Fu T, Keydar I, Cejas M, Wreschner D, Smorodinski M,Lopez M. (2004) A unique mucin immunoenhancing peptide with antitumor properties. Cancer Res. 64(21):8077-84.

Qin XQ, Tao N, Dergay A, Moy P, Fawell S, Davis A, Wilson JM, Barsoum B. (1998) Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Natl Acad Sci USA. 95(24):14411-16.

Rakhmilevich AL, Hooper AT, Hicklin DJ, Sondel PM. (2004) Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody. Mol Cancer Ther. 3(8):969-76.

Sarek G, Kurki S, Enbäck J, Iotzova G, Haas J, Laakkonen P, Laiho M, Ojala PM. (2007) Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J Clin Invest. 117(4):1019-28.

Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, Takahashi H. (1997) Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA. 94(12):6420-5.